Skip to main content
SpringerLink
Log in

A Risk-Benefit Assessment of HIV Protease Inhibitors

  • Review Article
  • Published:
Drug Safety Aims and scope Submit manuscript

Abstract

The use of triple therapy regimens, often called highly active antiretroviral therapy (HAART), generally involving 2 nucleoside analogues and an HIV protease inhibitor, have been endorsed as the standard of care for persons with HIV initiating therapy by a number of sets of international guidelines. The widespread availability of protease inhibitor-containing regimens has been associated with a dramatic drop in the incidence of new AIDS events and mortality throughout the developed world. Use of HAART regimens, particularly in treatment-naïve individuals, is also associated with dramatic reductions in HIV RNA load, rises in CD4+ cell numbers and improvements in some aspects of immune function.

However, protease inhibitor therapy is associated with a range of adverse effects, which varies between agents, and regimens frequently involve inconvenient administration schedules and disruption to patient’s lives. Thus, the undoubted benefits of antiretroviral therapy come at some cost in terms of both physical and psychological morbidity to the recipient. In assessing an individual for therapy, consideration of the risk of disease events and the benefit of therapy in reducing or preventing these events must be weighed against the potential of therapy to cause morbidity.

Using these criteria, we suggest that an individual with a 3 year risk of disease progression of less than 10% (based on CD4+ cell count and HIV RNA load) is more likely to a experience a morbidity if treated with HAART than if left untreated and monitored. For individuals with higher risks of HIV progression the risk versus benefit of initiating therapy may, in many cases, still be in favour of no therapy and continued observation. This will vary depending on the individuals risks (such as family and past medical history) and on the choice of agents in the regimen, some regimens having greater risks than others.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Volberding PA, Lagakos SW, Koch MA, et al. Zidovudine in asymptomatic human immunodeficiency virus infection — a controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. N Engl J Med 1990; 322: 941–9

    Article  PubMed  CAS  Google Scholar 

  2. Cooper DA, Gatell JM, Kroon S, et al. Zidovudine in persons with asymptomatic HIV infection and CD4+ cell counts greater than 400 per cubic millimeter. N Engl J Med 1993; 329: 297–303

    Article  PubMed  CAS  Google Scholar 

  3. Concorde Coordinating Committee. Concorde: MRC/ANRS randomized double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection. Lancet 1994; 343: 871–81

    Article  Google Scholar 

  4. Domingo P, Guariola JM, Ris R, et al. The impact of new antiretroviral regimens on HIV-associated hospital admissions and deaths. AIDS 1998; 12: 592–3

    Google Scholar 

  5. Moore RD, Bartlett JG. Combination antiretroviral therapy in HIV infection. Pharmacoeconomics 1996; 10: 109–13

    Article  PubMed  CAS  Google Scholar 

  6. Domingo P, Guariola JM, Ris R, et al. The impact of new antiretroviral regimens on HIV-associated hospital admissions and deaths. AIDS 1998; 12: 592–3

    Google Scholar 

  7. Carpenter CCJ, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1998. JAMA 1998; 280: 78–86

    Article  PubMed  CAS  Google Scholar 

  8. BHTVA Guidelines co-ordinating committee. British HIV Association guidelines for antiretroviral treatment of HIV seropositive individuals. Lancet 1997; 349: 1086–92

    Article  Google Scholar 

  9. Gazzard B, Moyle G on behalf of the BHIVA Guidelines Writing Committee. 1998 Revision to the British HIV Association Guidelines for antiretroviral treatment of HIV seropositive individuals. Lancet 1998; 352: 314–6

    Article  PubMed  CAS  Google Scholar 

  10. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997; 337: 725–33

    Article  PubMed  CAS  Google Scholar 

  11. Stellbrink H-J on behalf of the Invirase International Phase II Trial (SV-14604) Group. Clinical and survival benefit of saquinavir (SQV) in combination with zalcitabine (ddC) and zidovudine (ZDV) in untreated/minimally treated HIV-in-fected patients [abstract]. Sixth European Conference on Clinical Aspects and Treatment of HIV Infection; 1997 Oct 11–15: Hamburg

    Google Scholar 

  12. Cameron DW, Heath-Chiozzi M, Danner S, et al. Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. Lancet 1998; 351: 543–9

    Article  PubMed  CAS  Google Scholar 

  13. Moyle GJ, Gazzard BG, Cooper DA, et al. Antiretroviral therapy for HIV infection: a knowledge-based approach to drug selection and use. Drugs 1998; 55: 383–404

    Article  PubMed  CAS  Google Scholar 

  14. Cao Y, Qin L, Zhang L, et al. Virologic and immunologic characterization of long-term survivors of human immunodeficiency type 1 infection. N Engl J Med 1995; 332: 201–8

    Article  PubMed  CAS  Google Scholar 

  15. Pantaleo G, Menzo S, Vaccarezza M, et al. Studies in subject with long-term nonprogressive human immunodeficiency virus infection. N Engl J Med 1995; 332: 209–16

    Article  PubMed  CAS  Google Scholar 

  16. Craib KJP, Strathdee SA, Hogg RS, et al. Serum levels of human immunodeficiency virus type 1(HIV-1) RNA after seroconversion: a predictor of long-term mortality in HIV infection. J Infect Dis 1997; 176: 798–800

    Article  PubMed  CAS  Google Scholar 

  17. Mellors JW, Munoz A, Giorgi JV, et al. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997; 126: 946–54

    PubMed  CAS  Google Scholar 

  18. Stein DS, Lyles RH, Graham NMH, et al. Predicting clinical progression or death in subjects with early-stage human immunodeficiency virus (HIV) infection: a comparative analysis of quantification of HIV RNA, soluble tumor necrosis factor type II receptors, neopterin and (2-microglobulin. J Infect Dis 1997; 176: 1161–7

    Article  PubMed  CAS  Google Scholar 

  19. de Roda Husman AM, Koot M, Cornelissen M, et al. Association between CCR5 genotype and the clinical course of HIV-1 infection. Ann Intern Med 1997; 127: 882–90

    PubMed  Google Scholar 

  20. Lenderking WR, Gelber RD, Cotton DJ, et al. Evaluation of the quality of life associated with zidovudine treatment in asymptomatic human immunodeficiency virus infection. N Engl J Med 1994; 330: 738–4

    Article  PubMed  CAS  Google Scholar 

  21. Revicki DA, Moyle G, Stellbrink H-J, et al. Quality of life outcomes of combination zalcitabine-zidovudine, saquinavirzidovudine, and saquinavir-zalcitabine-zidovudine therapy for HIV-infected adults with CD4 counts between 50 and 350 per cubic millimeter. AIDS. In press

  22. Cohen C, Revicki DA, Nabulsi A, et al. and the Advanced HIV Disease Ritonavir Study Group. A randomised trial of the effect of Ritonavir in maintaining quality of life in advanced disease. AIDS 1998; 12: 1495–1502

    Article  PubMed  CAS  Google Scholar 

  23. Singh N, Squier C, Sivek C, Wagener M, et al. Determinants of adherence with antiretroviral therapy in patients with human immunodeficiency virus: prospective assessment with implications for enhancing adherence. AIDS Care 1996; 8(3): 261–9

    Article  PubMed  CAS  Google Scholar 

  24. Vanhove GF, Schapiro JM, Winters MA, et al. Patient compliance and drug failure in protease inhibitor monotherapy. JAMA 1996; 276; 1955–6

    Article  PubMed  CAS  Google Scholar 

  25. D—Aquila RT, Johnson VA, Welles SL, et al. Zidovudine resistance and HIV-1 disease progression during antiretroviral therapy. Ann Intern Med 1995; 122: 401–8

    Google Scholar 

  26. Moyle GJ. Viral resistance patterns selected by antiretroviral drugs and their potential to guide treatment choice. Exp Opin Invest Drugs 1997; 6: 943–64

    Article  CAS  Google Scholar 

  27. Finzi D, Hermankova M, Pierson T, et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997; 278: 1295–300

    Article  PubMed  CAS  Google Scholar 

  28. Autran B, Carcelain G, Li TS, et al. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science 1997; 277: 112–6

    Article  PubMed  CAS  Google Scholar 

  29. Pantaleo G. How immune-based interventions can change HIV therapy. Nature Med 1997; 3: 483–6

    Article  PubMed  CAS  Google Scholar 

  30. Connors M, Kovacs JA, Krevat S, et al. HIV infection induces changes in CD4+ T-cell phenotype and depletions within the CD4+ T-cell repertoire that are not immediately restored by antiviral or immune-based therapies. Nature Med 1997; 3: 533–40

    Article  PubMed  CAS  Google Scholar 

  31. Tural C, Romeu J, Sirera G, et al. Long-lasting remission of cytomegalovirus retinitis without maintenance therapy in human immunodeficiency virus infected patients. J Infect Dis 1998; 117: 1080–3

    Article  Google Scholar 

  32. Gill J, Moyle G, Nelson M. Discontinuation of MAC prophylaxis in patients with a rise in CD4 count following highly active anti-retroviral therapy (HAART). AIDS 1998; 12: 680

    PubMed  CAS  Google Scholar 

  33. Polis MA, Schrager L, Yoder C, et al. Virologic, immunologic and histologic responses to a 4-drug combination therapy in antiretroviral naïve HIV infected persons. 5th Conference on Retroviruses and Opportunistic Infections [abstract]. Chicago; 1998 Feb 1–5; 394, 152

    Google Scholar 

  34. Clerici M, Stocks NI, Zajac RA, et al. Detection of three distinct patterns of T helper cell dysfunction in asymptomatic, human immunodeficiency virus-seropositive patients. Independence of CD4+ cell numbers and disease staging. J Clin Invest 1989; 84: 1892–9

    Article  PubMed  CAS  Google Scholar 

  35. Coffin JM. HIV population dynamics in vivo: implications for genetic variation, pathogenesis and therapy. Science 1995; 267: 483–9

    Article  PubMed  CAS  Google Scholar 

  36. Delta Coordinating Committee. Delta: a randomised doubleblind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Lancet 1996; 348: 283–91

    Article  Google Scholar 

  37. Staszewski S, Morales-Ramirez J, Tashima K, et al. Aphase III, multicenter, randomized, open-label study to compare the antiretroviral activity and tolerability of efavirenz (EFV)+indinavir (INV) versus EFV+zidovudine (ZDV)+lamivudine (3TC) versus IDV+ZDV+3TC at 24 weeks [Study DMP266-006] [abstract 22336]. 12th World AIDS Conference; 1998 Jun 28–Jul 3: Geneva

    Google Scholar 

  38. Foster RH, Faulds, D. Abacavir. Drugs 1998; 55: 729–36

    Article  PubMed  CAS  Google Scholar 

  39. Hammer S, Katzenstein D, Hughes M, et al. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. N Engl J Med 1996; 335: 1081–90

    Article  PubMed  CAS  Google Scholar 

  40. CAESAR coordinating committee. Randomised trial of addition of lamivudine or lamivudine plus loviride to zidovudinecontaining regimens for patients with HIV-1 infection: the CAESAR trial. Lancet 1997; 349: 1413–21

    Article  Google Scholar 

  41. Bartlett JA, Benoit SL, Johnson VA, et al. Lamivudine plus zidovudine compared with zalcitabine plus zidovudine in patients with HIV infection. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1996; 125: 161–72

    PubMed  CAS  Google Scholar 

  42. Spruance SL, Pavia AT, Mellors JW, et al. Clinical efficacy of monotherapy with stavudine compared with zidovudine in HIV-infected, ZDV-experienced patients. Arandomised, double-blind, controlled trial. Ann Intern Med 1997; 126: 355–63

    PubMed  CAS  Google Scholar 

  43. Moyle GJ, Sadler M. Peripheral neuropathy with nucleoside antiretrovirals: risk factors, incidence and management. Drug Saf 1998; 19(6): 484–94

    Article  Google Scholar 

  44. Gulick RM, Mellors JW, Havlir D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with Human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997; 337: 743–39

    Article  Google Scholar 

  45. Moyle GJ, Youle M, Higgs C, et al. Safety, pharmacokinetics and antiretroviral activity of the potent, specific HIV protease inhibitor nelfinavir: results of a phase I/II trial and extended follow-up in HIV-infected patients. J Clin Pharmacol 1998; 38: 736–43

    PubMed  CAS  Google Scholar 

  46. Razzeca K, Odenheimer S, Davis M, et al. The treatment of nelfinavir (NFV) induced diarrhoea [abstract 12383]. 12th World AIDS Conference; 1998 Jun 28–Jul 3: Geneva

    Google Scholar 

  47. Petersen A, Johnson M, Clendennin N, et al. Comparison of BID and TID dosing of nelfinavir (NFV) in combination with stavudine (stavudine) and lamivudine (3TC): an interim look [abstract 373]. 5th Conference on Retroviruses and Opportunistic Infections; 1998 Feb 1–5: Chicago

    Google Scholar 

  48. Moyle G on behalf of the SPICE study team. Study of protease inhibitor combination in Europe (SPICE): saquinavir soft gelatin capsule (SQV-SGC) plus nelfinavir (NFV) in HIV infected individuals [abstract 12222]. 12th World AIDS Conference; 1998 Jun 28–Jul 3: Geneva

    Google Scholar 

  49. Reijers MHE, Weverling GJ, Jurriaans S, et al. Viral suppression with maintenance therapy after quadruple induction therapy in HIV-1 infected individuals: amsterdam duration of antiretroviral medication (ADAM) study. Lancet 1998; 352: 185–90

    Article  PubMed  CAS  Google Scholar 

  50. Gill MJ, on behalf of the NV15182 study team. Safety profile of soft gelatin capsule of saquinavir in combination with nucleosides in a broad patient population. AIDS 1998; 12: 1400–2

    PubMed  CAS  Google Scholar 

  51. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998; 12: F51–F8

    Article  PubMed  CAS  Google Scholar 

  52. Lo JC, Mulligan K, Tai VW, et al. ’Buffalo hump’ in men with fflV-I infection. Lancet 1998; 351: 867–70

    Article  PubMed  CAS  Google Scholar 

  53. Miller KD, Jones E, Yanovski JA, et al. Visceral abdominal-fat accumulation with use of indinavir. Lancet 1998; 351: 871–5

    Article  PubMed  CAS  Google Scholar 

  54. Viraben R, Aquilina C. Indinavir-associated lipodystrophy. AIDS 1998; 12: F37–F9

    Article  PubMed  CAS  Google Scholar 

  55. Herry I, Bernard L, de Truchis P. Hypertrophy of the breasts in a patient treated with indinavir. Clin Infect Dis 1997; 25: 937–8

    Article  PubMed  CAS  Google Scholar 

  56. Toma E, Therrien R. Gynaecomastia during indinavir antiretroviral therapy in HIV infection. AIDS 1998; 12: 681–2

    PubMed  CAS  Google Scholar 

  57. Dever LL, Oruwari PA, O’Donavan, et al. Hyperglycaemia associated with protease inhibitors in HIV-infected patients [abstract LB-8]. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1997 Sep 28–Oct 1: Toronto, Canada

    Google Scholar 

  58. Carr A, Cooper D, Thorisdottir A, et al. Prevalence and severity of protease inhibitor (PI) induced lipodystrophy and insulin resistance [abstract 12462]. 12th World AIDS Conference; 1998 Jun 28–Jul 3: Geneva

    Google Scholar 

  59. Caldwell R, Rothstein A, Allmon C, et al. Evaluation of protease inhibitor associated hyperglycaemia in a University-based HIV clinic [abstract 12395]. 12th World AIDS Conference; 1998 Jun 28–Jul 3: Geneva

    Google Scholar 

  60. Sullivan AK, Feher MD, Nelson MR, et al. Marked hypertriglyceridaemia associated with ritonavir therapy. AIDS 1998; 12: 1393–4

    Article  PubMed  CAS  Google Scholar 

  61. Chang E, Deleo M, Liu YT, et al. The effects of antiretroviral protease inhibitors (PIs) on serum lipids and glucose in HIV-infected persons [abstract 12381]. 12th World AIDS Conference; 1998 Jun 28–Jul 3: Geneva

    Google Scholar 

  62. Nelson MR, Moyle G, Newell A, et al. The incidence of hyperlipidaemia with protease inhibitors [abstract I-87]: 30th Interscience Conference on Antimicrobial Agents and Chemotherapy. 1998 Sep 24–27: San Diego: 389

    Google Scholar 

  63. Rothstein AM, Caldwell RD, Allmaon C, et al. Investigation of protease inhibitor-associated hypercholesterolaemia in a University-based HIV clinic [abstract I-91]. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). 1998 Sep 24–27: San Diego: 390

    Google Scholar 

  64. Henry K, Melroe H, Huebsch J, et al. Severe premature coronary artery disease with protease inhibitors. Lancet 1998; 351: 1328

    Article  PubMed  CAS  Google Scholar 

  65. Carr A, Samaras K, Chisholm DJ, et al. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia and insulin resistance. Lancet 1998; 352: 1881–3

    Article  Google Scholar 

  66. Prazuck T, Semaille C, Roques S. Fatal haemolysis in an AIDS patient treated with indinavir. AIDS 1998; 12: 531–3

    PubMed  CAS  Google Scholar 

  67. HIV protease inhibitors and patients with haemophilia. Letter to healthcare providers. US Food and Drug Administration; July 17 1996

  68. Stanworth SJ, Bolton MJ, Hay CRM, et al. Increased bleeding in HIV-positive haemophiliacs treated with antiretroviral protease inhibitors. Haemophilia 1998; 4: 109–14

    Article  PubMed  CAS  Google Scholar 

  69. Bonfanti P, Capetti A, Riva P, et al. Hypersensitivity reactions during antiretroviral regimens with protease inhibitors. AIDS 1997; 11: 1301–2

    PubMed  CAS  Google Scholar 

  70. Rijnders B, Kooman J. Severe allergic reaction after repeated exposure to indinavir. Clin Infect Dis 1998; 26: 523–4

    Article  PubMed  CAS  Google Scholar 

  71. Murphy M, Armstrong D, Sepkowitz KA, et al. Regression of AIDS-related Kaposi’s sarcoma following treatment with an HIV-protease inhibitor. AIDS 1997; 11: 261–2

    PubMed  CAS  Google Scholar 

  72. Hicks CB, Myers SA, Giner J. Resolution of intractable molluscum contagiosum in a human immunodeficiency virus infected patient after institution of antiretroviral therapy with ritonavir. Clin Infect Dis 1997; 24: 1023–5

    Article  PubMed  CAS  Google Scholar 

  73. Jacobsen MA, Zrgans M, Pavan PR, et al. Cytomegalovirus retinitis after initiation of highly active antiretroviral therapy. Lancet 1997; 349: 1443–5

    Article  Google Scholar 

  74. Nussenblatt RB, Lane HC. Human immunodeficiency virus disease: changing patterns of intraocular inflammation. Am J Ophthalmol 1998; 125: 374–82

    Article  PubMed  CAS  Google Scholar 

  75. Race EM, Adelson-Mitty J, Kriegel GR, et al. Focal mycobacterial lymphadenitis following initiation of protease-inhibitor therapy in patients with advanced HIV-1 disease. Lancet 1998; 351: 252–5

    Article  PubMed  CAS  Google Scholar 

  76. Kopp JB, Miller KD, Mican JAM, et al. Crystalluria and urinary tract abnormalities associated with indinavir. Ann Intern Med 1997; 127: 119–25

    PubMed  CAS  Google Scholar 

  77. Tashima KT, Horowitz JD, Rosen S. Indinavir nephropathy. N Engl J Med 1997; 336: 138–9

    Article  PubMed  CAS  Google Scholar 

  78. Bach MC, Godofsky EW. Indinavir nephrolithiasis in warm climates. J AIDS 1997; 14: 296–97

    CAS  Google Scholar 

  79. Berns JS, Cohen RM, Silverman M, et al. Acute renal failure due to indinavir crystalluria and nephrolithiasis: a report of 2 cases. Am J Kidney Dis 1997; 30: 558–60

    Article  PubMed  CAS  Google Scholar 

  80. Reitsma WJ. Fever, erythroderma, abdominal pain and renal failure following initiation of indinavir therapy. Clin Infect Dis 1997; 25: 1268–9

    Article  Google Scholar 

  81. Asher DP, Lucy MD. Indinavir sulphate renal toxicity in a paediatric haemophiliac with HIV infection. Ann Pharmacother 1997; 31: 1146–9

    Google Scholar 

  82. Chen SCA, Nankivell BJ, Dwyer DE. Indinavir-induced renal failure. AIDS 1998; 12: 440–1

    PubMed  CAS  Google Scholar 

  83. Grunke M, Valerius T, Manger B, et al. Renal dysfunction in a HIV-infected patient who was treated with indinavir. Clin Infect Dis 1997; 25: 1270–1

    Article  PubMed  CAS  Google Scholar 

  84. Juerissen FJF, Schneider MME, Borleffs JCC. Is the combination of hepatitis and indinavir potentially dangerous? AIDS 1998; 12: 441–2

    Google Scholar 

  85. Merck Sharpe & Dohme. European Summary of Product Characteristics for Indinavir. White House Station (NJ), USA

  86. Casada JL, Perez-Elias MJ, Antlea A. Risk factors for ritonavir intolerance and outcome after change to indinavir. AIDS 1998; 12: 335–6

    Google Scholar 

  87. Van Hove G, Arribas JR, Lazzarin A, et al. Effect of dose escalation on the safety, tolerability and efficacy of ritonavir [abstract 12283]. 12th World AIDS Conference; 1998 Jun 28–Jul 3: Geneva

    Google Scholar 

  88. Arribas JR, Ibanez C, Ruiz-Antoran B, et al. Acute hepatitis in HIV-infected patients during ritonavir therapy. AIDS 1998; 12: 1722–4

    PubMed  CAS  Google Scholar 

  89. Haubrich R, Lalezari J, Follansbee SE, et al. Improved survival and reduced clinical progression in HIV-infected patients with advanced disease treated with saquinavir plus zalcitabine. Antiviral Ther 1998; 3: 33–42

    CAS  Google Scholar 

  90. Markowitz M, Conant M, Hurley A, et al. A preliminary evaluation of nelfinavir mesylate, an inhibitor of human immunodeficiency virus (HTV)-1 protease, to treat HIV infection. J Infect Dis 1998; 117: 1533–40

    Article  Google Scholar 

  91. Moyle GJ. The role of combinations of HIV protease inhibitors in management of persons with HIV infection. Exp Opin Invest Drugs 1998; 7: 413–26

    Article  CAS  Google Scholar 

  92. Eisen S, Miller D, Woodward R, et al. The effect of prescribed daily dose frequency on patient medication compliance. Ann Intern Med 1990; 150; 1881–4

    Article  CAS  Google Scholar 

  93. Rudd P, Ahmed S, Zachery V, et al. Improved compliance measures: applications in an ambulatory hypertensive trial. Clin Pharmacol Ther 1990; 48: 676–85

    Article  PubMed  CAS  Google Scholar 

  94. Walsh JC, Dalton M, Gill J, et al. Adherence to highly active antiretroviral therapy (HAART) [abstract 1-171] 38th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). 1998 Sep 24–27: San Diego: 419

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Chelsea and Westminster Hospital, 369 Fulham Road, London, SW10 9NH, England

    Graeme J. Moyle & Brian G. Gazzard

Authors
  1. Graeme J. Moyle
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Brian G. Gazzard
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Moyle, G.J., Gazzard, B.G. A Risk-Benefit Assessment of HIV Protease Inhibitors. Drug-Safety 20, 299–321 (1999). https://doi.org/10.2165/00002018-199920040-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002018-199920040-00002

Keywords

Search

Navigation